Updated immunisation reference: Australian Immunisation Register (AIR)

MVEC has recently updated its reference page on the Australian Immunisation Register (AIR).

The updated page includes information about new fields added in 2024, and general guidance on how to use AIR, and what it should be used for.

MVEC: Australian Immunisation Register (AIR)


Trending immunisation resources: Shoulder injury related to vaccine administration (SIRVA)

SIRVAs are a rare but serious complication following suspected inadvertent administration of a vaccine too high in the deltoid or into the shoulder joint. This can lead to a local inflammatory response and potential trauma to local structures within the shoulder. Implications of SIRVA can include long-term pain and restricted movement, difficulty with completing activities of daily living/caring for others, time off work, loss of income, inability to participate in sports/hobbies and impacts on the social and emotional wellbeing of the affected person. 

Ensuring a correct injection technique can prevent SIRVA from occurring in the first place. We encourage vaccine providers to familiarise themselves with MVEC’s Administration of injected vaccines – correct technique reference page for guidance on identifying the correct injection site.  

Further information on SIRVA, including diagnosis and treatment, can be found on our SIRVA immunisation reference page. We also encourage providers to complete our free Education Portal eLearning package on SIRVA. 


अद्यतित प्रतिरक्षण संदर्भ पृष्ठ: रोटावायरस

Rotavirus infections are the leading cause of dehydrating gastroenteritis in young children. Rotaviruses belong to the genus रोटावायरस (in the family Reoviridae) which comprises eight species, referred to as A, B, C, D, E, F, G and H.

MVEC has recently updated its reference page on rotavirus. The updated page includes more details on rotavirus symptoms, transmission and epidemiology. There is detail guidance on vaccine considerations, side effects, precautions and contraindications, as well as links to helpful resources.

एमवीईसी: रोटावायरस


Updated immunisation reference page: Translated influenza pages

MVEC has recently published translated versions of our 2024 influenza reference page. The page is available to read in Vietnamese, Hindi and Simplified Chinese.

The reference page details recommendations for flu vaccination in 2024, including: 

  • influenza strains included in this year’s vaccines 
  • brands available by age and funding 
  • commonly asked questions. 

Switch between languages using the dropdown box on the page: एमवीईसी: इन्फ्लुएंजा 


New reference page: West Metro Health Services Partnership campaign

MVEC has recently published a new immunisation reference page, hosting the West Metro Health Services Partnership’s (WMHSP) campaign on COVID-19 and influenza vaccination advice for people with low vaccination rates.

The page includes advice provided by doctors at the Royal Melbourne Hospital, the Peter MacCallum Cancer Centre and the Royal Children’s Hospital.

WMHSP: COVID-19 and influenza vaccination advice for people with low vaccination rates 


Updated immunisation reference page: Q fever

MVEC has updated its Q fever reference page to reflect the recent closure of the Australian Q Fever Register.

All Q fever vaccines administered should now be reported exclusively to the Australian Immunisation Register (AIR). Those who have previously been vaccinated against Q fever, or who have previously registered their natural immunity on the Australian Q Fever Register, should ensure their AIR record is up to date.

MVEC: Q fever records now to be added to AIR 
MVEC: Q fever


Updated immunisation reference page: Vaccine-associated enhanced disease

MVEC has recently updated its reference page on vaccine-associated enhanced disease (VAED).

VAED is a rare phenomenon where a person who has been vaccinated experiences a more severe clinical presentation of an infection than would normally be seen in an unvaccinated person.

The new page includes more detailed information on VAED diagnosis, and vaccines that have been associated with VAED.

MVEC: Vaccine-associated enhanced diseased


New immunisation reference page: Specialist immunisation services

MVEC has recently published a new reference page with information about specialist immunisation services available in Victoria. 

Specialist immunisation services are hospital-based immunisation clinics led by a team of specialised medical and nursing staff with expertise in vaccines and immunisation. 

MVEC’s new page provides information about accessing the Victorian services.

MVEC: Specialist immunisation services 


अद्यतित टीकाकरण संदर्भ पृष्ठ: इन्फ्लुएंजा

Influenza virus can cause infections resulting in a spectrum of symptoms, from mild cough and cold features to systemic illnesses with multiple complications. Pregnant women, children under 5 years, those aged over 65 years, people with underlying medical conditions, and Aboriginal and Torres Strait Islander peoples carry the highest rates of morbidity and mortality within Australia. Annual vaccination is recommended for everyone aged 6 months and over.

MVEC has recently updated its influenza reference page to detail the recommendations for vaccination in 2024, including the influenza strains included in this year’s vaccines, the vaccine brands available by age and funding, and commonly asked questions.

एमवीईसी: इन्फ्लुएंजा
(NB: translated versions of the updated influenza reference page will be available soon)


Updated immunisation reference page: Respiratory syncytial virus (RSV)

Respiratory syncytial virus (RSV) is a virus that causes both upper and lower respiratory tract infections. Children under 1 year of age, individuals with underlying medical conditions (e.g. chronic cardiac and lung disease), the older population and immunocompromised people are more likely to experience serious disease requiring hospitalisation. 

MVEC has recently updated its RSV reference page to include information on the administration of Arexvy, the only RSV vaccine available in Australia. This vaccine is registered for use in all adults aged 60 years and over and is specifically recommended for certain populations. 

MVEC: Respiratory Syncytial Virus (RSV)